Amgen: Q4 EPS up 15%

(CercleFinance.com) - Amgen reports Q4 2023 non-GAAP EPS that is up 15% to $4.
71, with a non-GAAP operating margin improving 0.8 point to 46.7% on revenues that are up 20% to $8.2bn.

The biotech group's product sales rose 23% in volumes, driven by double-digit growth for its Blincyto, Evenity, Repatha and Prolia products, while average selling prices contracted by 0.3%.

With FY 2023 adjusted EPS of $18.65 and revenues of $28.2bn, Amgen expects to achieve target ranges of $18.90-20.30 and $32.4bn-$33.8bn respectively for the year ahead.


Copyright (c) 2024 CercleFinance.com. All rights reserved.